Skip to content
Menu

Head-to-head comparison

MEDVidi vs Pallas Health

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #470
MEDVidi

MEDVidi is a US telehealth platform whose licensed providers evaluate patients and prescribe GLP-1 weight-management medications, including brand-name Zepbound (tirzepatide) and Wegovy (semaglutide).

Marked down on: Consult-fee model: medication is not included and its cost is separate

vs
Ranked #11Desk pick
Pallas Health

Pallas Health names all six of the pharmacies that dispense for it and two prescribing clinicians whose NPIs verify in the federal registry — then sells every GLP-1 on a single twelve-week prepay, so the advertised “/mo average” is one $597 or $897 charge divided by three.

$199/mo (see conditions) sema · $299/mo (see conditions) tirz · Verified August 2026

Marked down on: There is no month-to-month rung for either compounded molecule — the funnel renders no cadence selector — so the advertised “$199/mo average” is a single $597 charge every twelve weeks divided by three

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 52/100 (C) for MEDVidi. MEDVidi still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

MEDVidi

52/100

C

Overall

Pallas Health

87/100

B+

Price transparency

30
78

State access

24
94

Molecule range

79
90

Onboarding speed

66
88

Support responsiveness

70
88

Licensing & trust

68
90

The spec sheet

FieldMEDVidiPallas Health
SemaglutideNot listed on MEDVidi's site (checked July 2026)$199/mosee conditions$199/mo average (compounded injectable; $597 billed every 12 weeks after $139 for the first 4 weeks; no month-to-month tier is sold)
TirzepatideNot listed on MEDVidi's site (checked July 2026)$299/mosee conditions$299/mo average (compounded injectable; $897 billed every 12 weeks after $179 for the first 4 weeks; no month-to-month tier is sold)
CoverageNot listed on MEDVidi's site (checked July 2026)All 50 states + DC (async in 43; 7 states plus DC require one video visit)
Brand-nameYesYes
Oral optionInjectable onlyInjectable only
Best forPeople who want a licensed provider to prescribe brand glp-1 they fill with insurance.Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.
Desk Score52/100C87/100B+

The verdict

Desk pick — Pallas Health

Pallas Health takes this head-to-head with the higher Desk Score, 87/100 (B+) against 52/100 (C) for MEDVidi. MEDVidi still holds its ground where its strengths line up with yours.

Choose MEDVidi if…

People who want a licensed provider to prescribe brand glp-1 they fill with insurance.

Choose Pallas Health if…

Readers who weight named pharmacies and independently verifiable prescribers above cash-flow flexibility, and who can absorb a $597 or $897 charge every twelve weeks rather than a monthly one.

$199/mo (see conditions) sema · $299/mo (see conditions) tirz · All 50 states + DC (async in 43; 7 states plus DC require one video visit)

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: MEDVidi · Pallas Health.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.